[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

On 05 Aug 2025, Haleon plc (HLN) filed a Form 6-K confirming execution of the second tranche of its share-buyback programme announced 31 Jul 2025. On 04 Aug 2025 the company repurchased 1,418,324 ordinary shares on the London Stock Exchange for cancellation. Purchase prices ranged from 355.90p to 364.60p, with a volume-weighted average of 358.534p. After settlement, issued share capital stands at 8,984,952,236 shares of £0.01 each; 3,880,205 shares are held in treasury, leaving 8,981,072,031 shares entitled to vote. A detailed trade log is available via the LSE RNS link and on Haleon’s investor site. No additional financial results or forward guidance were provided.

Positive

• Execution of second-tranche buyback demonstrates ongoing capital-return commitment
• Cancellation of shares reduces outstanding voting stock, marginally supporting EPS

Negative

• Scale is immaterial—1.4 M shares equal just 0.016% of float, limiting financial impact
• Cash outflow for buyback not accompanied by disclosure on funding or leverage effects

Insights

Financial Analyst

TL;DR: Minor buyback; 1.4 M shares retired—immaterial to EPS, but signals ongoing shareholder-return policy.

The repurchase equals roughly 0.016% of Haleon’s 9 B share base, so immediate EPS accretion is negligible. Nevertheless, it demonstrates management’s commitment to the July 2025 buyback plan and provides incremental support to the share price. Cash deployment is modest; no impact on leverage metrics disclosed. Overall, this is a routine capital-allocation action with limited valuation effect.

Corporate Governance Expert

TL;DR: Filing meets UK MAR disclosure rules; share count update aids transparency.

The 6-K satisfies Article 5 UK MAR by publishing full trade details and refreshed voting-rights figure. Transparency helps investors track threshold crossings under FCA DTR 5. There are no governance red flags and the company continues to use authorised capital efficiently. Impact on control dynamics is de minimis given the tiny percentage repurchased.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	05 August 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

05 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,418,324 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	04 August 2025	04 August 2025	04 August 2025
Number of Shares purchased:	1,418,324	-	-
Highest price paid per Share (p):	364.6000	-	-
Lowest price paid per Share (p):	355.9000	-	-
Volume weighted average price paid per Share (p):	358.5340	-	-

Following the settlement of the above, the Company's registered share capital is 8,984,952,236 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,981,072,031 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below: 

http://www.rns-pdf.londonstockexchange.com/rns/9219T_1-2025-8-4.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: August 05, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many Haleon (HLN) shares were repurchased on 04 Aug 2025?

1,418,324 ordinary shares were bought on the London Stock Exchange for cancellation.

What was the volume-weighted average price paid per HLN share?

The VWAP was 358.534 pence per share.

How many voting shares does Haleon have after the buyback?

The company now has 8,981,072,031 ordinary shares with voting rights.

Is this buyback part of a larger programme?

Yes. It forms part of the second tranche of the share-buyback programme announced on 31 Jul 2025.

Where can investors find the detailed trade breakdown?

A full list of individual trades is available at the LSE RNS link http://www.rns-pdf.londonstockexchange.com/rns/9219T_1-2025-8-4.pdf and on Haleon’s investor website.